目的分析终末期肝病模型(model for end-stage liver disease,MELD)评估我国慢性乙型重型肝炎患者预后的临床价值。方法回顾性分析2006年1月至2008年12月5家医院收治的慢性乙型重型肝炎住院患者561例临床资料,分为生存组和死亡组,计算...目的分析终末期肝病模型(model for end-stage liver disease,MELD)评估我国慢性乙型重型肝炎患者预后的临床价值。方法回顾性分析2006年1月至2008年12月5家医院收治的慢性乙型重型肝炎住院患者561例临床资料,分为生存组和死亡组,计算患者入院时的MELD评分,应用t’检验、Logistic回归分析、受试者工作特征(receiver operating characteristic curve,ROC)曲线下面积(area under curve,AUC)评价MELD对慢性乙型重型肝炎预后的预测价值。结果生存组的MELD分值为(22.25±4.35),死亡组MELD分值为(28.94±8.76),差异有统计学意义(P<0.01)。Logistic回归分析表明,在其他影响因素均衡的条件下,MELD分值每增加1,死亡的可能性增加至1.182倍,MELD评分的Logistic回归方程预测预后总的正确率为68.4%,且差异有统计学意义(P<0.01);MELD评分的AUC为0.759,95%置信区间为(0.720～0.798),MELD界值为27,其诊断的正确度为中等。结论 MELD评分系统预测我国慢性乙型重型肝炎患者的预后有临床应用价值,但效能中等。展开更多
目的分析肝硬化肠道微生态的研究现状、热点及前沿趋势。方法检索Web of Science(WOS)核心数据库建库至2020年12月31日的肝硬化肠道微生态研究的英文文章。通过文献计量分析软件VOSviewer分析发文国家、机构、作者和本研究领域的热点和...目的分析肝硬化肠道微生态的研究现状、热点及前沿趋势。方法检索Web of Science(WOS)核心数据库建库至2020年12月31日的肝硬化肠道微生态研究的英文文章。通过文献计量分析软件VOSviewer分析发文国家、机构、作者和本研究领域的热点和前沿方向。结果共检索到848篇文章。美国的Virginia Commonwealth University是肝硬化肠道微生态相关文章发表最多的机构。国外学者Bajaj JS在该领域发文量最高。肝硬化肠道微生态相关研究在《Hepatology》上的发表数量最多,为48篇。研究热点可概括为肝性脑病、代谢性肝病、菌群失衡与炎症感染等。结论通过对肝硬化肠道微生态研究热点和新兴趋势进行可视化分析,为肝硬化肠道微生态的研究人员及研究单位提供了研究方向及潜在合作可能。展开更多
Objective:To observe the changes of symptoms,Chinese medicine(CM)syndrome,and lung inflammation absorption during convalescence in patients with coronavirus disease 2019(COVID-19)who had not totally recovered after ho...Objective:To observe the changes of symptoms,Chinese medicine(CM)syndrome,and lung inflammation absorption during convalescence in patients with coronavirus disease 2019(COVID-19)who had not totally recovered after hospital discharge and whether CM could promote the improvement process.Methods:This study was designed as a prospective cohort and nested case-control study.A total of 96 eligible patients with COVID-19 in convalescence were enrolled from Beijing Youan Hospital and Beijing Huimin Hospital and followed up from the hospital discharged day.Patients were divided into the CM(64 cases)and the control groups(32 cases)based on the treatment with or without CM and followed up at 14,28,56,and 84 days after discharge.In the CM group,patients received the 28-day CM treatment according to two types of CM syndrome.Improvements in clinical symptoms,CM syndrome,and absorption of lung inflammation were observed.Results:All the 96 patients completed the 84-day follow-up from January 21 to March 28,2020.By the 84th day of follow-up,respiratory symptoms were less than 5%.There was no significant difference in the improvement rates of symptoms,including fatigue,sputum,cough,dry throat,thirst,and upset,between the two groups(P>0.05).Totally 82 patients(85.42%)showed complete lung inflammation absorption at the 84-day follow-up.On day 14,the CM group had a significantly higher absorption rate than the control group(P<0.05)and the relative risk of absorption for CM vs.control group was 3.029(95%confidence interval:1.026-8.940).The proportions of CM syndrome types changed with time prolonging:the proportion of the pathogen residue syndrome gradually decreased,and the proportion of both qi and yin deficiency syndrome gradually increased.Conclusions:Patients with COVID-19 in convalescence had symptoms and lung inflammation after hospital discharge and recovered with time prolonging.CM could improve lung inflammation for early recovery.The types of CM syndrome can be transformed with time prolonging.展开更多
基金Supported by the National Key Research and Development Project(No.2020YFC0841600,2020YFC0841500)National Science and Technology Major Project(No.2017ZX10305501)Project of Beijing Adm inistration of Traditional Chinese Medicine(No.YJ2020-02)。
文摘Objective:To observe the changes of symptoms,Chinese medicine(CM)syndrome,and lung inflammation absorption during convalescence in patients with coronavirus disease 2019(COVID-19)who had not totally recovered after hospital discharge and whether CM could promote the improvement process.Methods:This study was designed as a prospective cohort and nested case-control study.A total of 96 eligible patients with COVID-19 in convalescence were enrolled from Beijing Youan Hospital and Beijing Huimin Hospital and followed up from the hospital discharged day.Patients were divided into the CM(64 cases)and the control groups(32 cases)based on the treatment with or without CM and followed up at 14,28,56,and 84 days after discharge.In the CM group,patients received the 28-day CM treatment according to two types of CM syndrome.Improvements in clinical symptoms,CM syndrome,and absorption of lung inflammation were observed.Results:All the 96 patients completed the 84-day follow-up from January 21 to March 28,2020.By the 84th day of follow-up,respiratory symptoms were less than 5%.There was no significant difference in the improvement rates of symptoms,including fatigue,sputum,cough,dry throat,thirst,and upset,between the two groups(P>0.05).Totally 82 patients(85.42%)showed complete lung inflammation absorption at the 84-day follow-up.On day 14,the CM group had a significantly higher absorption rate than the control group(P<0.05)and the relative risk of absorption for CM vs.control group was 3.029(95%confidence interval:1.026-8.940).The proportions of CM syndrome types changed with time prolonging:the proportion of the pathogen residue syndrome gradually decreased,and the proportion of both qi and yin deficiency syndrome gradually increased.Conclusions:Patients with COVID-19 in convalescence had symptoms and lung inflammation after hospital discharge and recovered with time prolonging.CM could improve lung inflammation for early recovery.The types of CM syndrome can be transformed with time prolonging.
